Altasciences and VoxCell BioInnovation have announced a strategic collaboration aimed at transforming preclinical drug development by integrating advanced 3D bioprinted tissue models into early-phase research.
The partnership combines Altasciences’ full-service early-stage drug development capabilities with VoxCell’s proprietary 3D tissue modeling technology to create a more predictive and human-relevant testing environment. The goal: to speed up the drug discovery process and improve the success rate of new therapies as they progress toward clinical trials.
“We’re proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This collaboration aligns with our commitment to the 3Rs and to innovative solutions that improve data quality and accelerate decisions for our clients.”
VoxCell’s high-resolution bioprinted tissues are designed to closely replicate the structure and behavior of human tumors and other biological tissues. These models provide drug developers with a powerful platform to evaluate drug efficacy, safety, and toxicity prior to initiating animal or human studies.
“Our mission has always been to make drug screening more human-relevant and predictive,” said Karolina Valente, CEO of VoxCell BioInnovation. “Altasciences shares this forward-thinking approach, and we’re excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.”
Initially, the collaboration will focus on drug screening for ocular diseases, with plans to expand into other therapeutic areas in the future.
The partnership reflects a shared commitment to innovation, efficiency, and smarter science—ultimately aiming to accelerate drug development and improve outcomes for patients worldwide.